BioNTech SE (22UA) — Free Cash Flow Generation Index

Latest as of December 2025: 0.80x

BioNTech SE (22UA) has a Free Cash Flow Generation Index of 0.80x as of December 2025. Free cash flow of €247.40 Million represents 1% of operating cash flow (€309.50 Million). Explore reinvestment intensity of BioNTech SE to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.80x
Free Cash Flow / Operating CF

Free Cash Flow

€247.40 Million
EUR

Operating Cash Flow

€309.50 Million
EUR

Capital Expenditures

€62.10 Million
EUR

BioNTech SE Free Cash Flow Generation Index (2021–2025)

Historical FCF Generation Index trend for BioNTech SE across 5 annual periods. For the full cash flow conversion analysis, see cash flow conversion of BioNTech SE.

Annual Free Cash Flow Generation for BioNTech SE (2021–2025)

Year-by-year Free Cash Flow Generation Index for BioNTech SE. Check BioNTech SE cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (EUR) Operating CF Capital Expenditures YoY Change
2025 -0.64x €-293.00 Million €456.00 Million €749.00 Million ▲ +45.4%
2024 -1.18x €-244.60 Million €207.70 Million €452.30 Million ▼ -235.6%
2023 0.87x €4.67 Billion €5.37 Billion €705.50 Million ▼ -10.7%
2022 0.97x €13.21 Billion €13.58 Billion €363.30 Million ▲ +17.7%
2021 0.83x €735.70 Million €889.70 Million €127.50 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).